Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Coya Therapeutics, Inc. logo — Unleashing the power of Tregs to tackle neurodegenerative an...

Coya Therapeutics, Inc.

Unleashing the power of Tregs to tackle neurodegenerative and autoimmune diseases.

Founded 2020 United States Houston, United States 17 employees Unknown Total: $108.15M Biopharma, Biotechnology +1

General Information

Company Name Coya Therapeutics, Inc.
Founded Year 2020
Location United States Houston, United States +1
Employees 17
Industries Biopharma, Biotechnology, Life Sciences
Funding Stage Unknown
Social

Get notified when Coya Therapeutics, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Coya Therapeutics, Inc.

Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya’s product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya’s 300 Series product candidates, COYA 301 and COYA 302, are biologic therapies intended to enhance Treg function and expand Treg numbers. COYA 301 is a cytokine biologic for subcutaneous administration to enhance Treg function and expand Treg numbers in vivo, and COYA 302 is a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages. These two mechanisms may be additive or synergistic in suppressing inflammation. Coya’s mission is focused on the advancement of innovative therapeutic approaches to address the significant unmet medical needs of patients with serious neurodegenerative, autoimmune, and metabolic diseases. For more information about Coya, please visit www.coyatherapeutics.com.

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Private Placement Non Vc •••••• 2
Investor Investor
01 Jan 2026
Post Ipo Equity •••••• - 01 Oct 2025
Private Placement Non Vc •••••• - 01 Oct 2024
Post Ipo Equity •••••• 1
Investor
01 May 2024
Private Placement Non Vc •••••• - 01 Dec 2023

View All 9 Funding Rounds

FAQ About Coya Therapeutics, Inc.

Unleashing the power of Tregs to tackle neurodegenerative and autoimmune diseases.
Coya Therapeutics, Inc. was founded in 2020.
Coya Therapeutics, Inc. is headquartered in Houston, United States.
Coya Therapeutics, Inc. operates in the following industries: Biopharma, Biotechnology, Life Sciences.
Coya Therapeutics, Inc. has approximately 17 employees.
Coya Therapeutics, Inc. has completed 9 funding rounds, raising a total of $108.15M. The latest funding stage is Unknown.

We're actively collecting intelligence on Coya Therapeutics, Inc..

Track Coya Therapeutics, Inc. to get notified

Don't just browse. Track.

Signal Tracker monitors Coya Therapeutics, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes